— Know what they know.
Not Investment Advice

ZOM AMEX

Zomedica Corp.
1W: -4.4% 1M: -39.2% 3M: -51.1% 1Y: -59.4% 3Y: -82.3% 5Y: -64.7%
$0.10
Last traded 2025-04-01 — delisted
AMEX · Healthcare · Drug Manufacturers - Specialty & Generic · $95.3M mcap · 962M float · 0.888% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$95.3M
52W Range0.0151-0.1952
Volume790,936
Avg Volume8,541,418
Beta1.16
Dividend—
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOLarry C. Heaton II
Employees144
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2017-11-21
100 Phoenix Drive
Ann Arbor, MI 48108
US
734 369 2555
About Zomedica Corp.

Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals. The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses. Additionally, Zomedica provides PulseVet, a system used to address a range of musculoskeletal conditions such as fractures, tendonitis, and torn ligaments in horses and smaller animals. Zomedica also maintains collaborative agreements, including one with Celsee, Inc. for the joint development and commercialization of liquid biopsy assays and consumables for detecting cancer in pets, and another with Seraph Biosciences, Inc. for the development and marketing of a novel pathogen detection system. Established in 2015 and based in Ann Arbor, Michigan, the company was formerly known as Zomedica Pharmaceuticals Corp. before adopting its current name in October 2020.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Rowe Jeffrey M P-Purchase 731,368 $0.07 2025-03-17
Rowe Jeffrey M P-Purchase 34,725 $0.07 2025-03-17
Rowe Jeffrey M P-Purchase 4,265 $0.07 2025-03-17
Rowe Jeffrey M P-Purchase 68,000 $0.07 2025-03-17
Rowe Jeffrey M P-Purchase 100,647 $0.07 2025-03-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms